Hematopathology Practice Questions

Q: A blood grouping test shows clumping with Anti-A serum, clumping with Anti-B serum, and no clumping in the control. What blood group does this indicate?

AB. ***AB*** - The results show **clumping with both Anti-A and Anti-B serum**, indicating the presence of both A and B antigens on the red blood cells. - The absence of clumping in the control confirms that the **agglutination with Anti-A and Anti-B is due to specific antigen-antibody reactions**, not nonspecific agglutination. - Blood group AB individuals have both A and B antigens on their RBCs and no anti-A or anti-B antibodies in their serum. *A* - Blood group A would show **clumping with Anti-A serum only** and no clumping with Anti-B serum. - This is incorrect because the sample shows clumping with both antisera. *B* - Blood group B would show **clumping with Anti-B serum only** and no clumping with Anti-A serum. - This is incorrect because the sample shows clumping with both antisera. *O* - Blood group O would show **no clumping with either Anti-A or Anti-B serum**, as it lacks both A and B antigens. - This is incorrect because the sample clearly shows clumping with both Anti-A and Anti-B sera.

Q: Which disease is characterized by the absence of the CD59 protein?

Paroxysmal Nocturnal Hemoglobinuria (PNH). ***PNH*** - CD59 is a **glycoprotein** that inhibits the formation of the membrane attack complex of the complement system, which is deficient in **Paroxysmal Nocturnal Hemoglobinuria (PNH)** [1][2]. - The presence of CD59 deficiency leads to **hemolysis** and manifestations like **dark urine**, especially in the morning [1]. *BRR* - Refers to **Bloom-Richardson Grade** in breast cancer pathology, not related to CD59. - It focuses more on **histological features** rather than specific **markers** like CD59. *PTEN* - PTEN is a **tumor suppressor gene** associated with various cancers, particularly in **Cowden syndrome** and **PTEN hamartoma syndrome**. - It does not relate to the **CD59 deficiency** found in PNH. *Cowden syndrome* - Cowden syndrome is linked to mutations in the **PTEN gene**, leading to numerous hamartomas and an increased risk for breast and thyroid cancers. - It does not exhibit any relationship with **CD59**, which is specifically associated with PNH. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 650-651. [2] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Blood And Bone Marrow Disease, pp. 601-602.

Q: Which of the following statements about sideroblastic anemia is correct?

Prussian blue staining reveals ringed sideroblasts. ***Prussian blue staining reveals ringed sideroblasts*** - Sideroblastic anemia is characterized by the presence of **ringed sideroblasts** in the bone marrow, which are erythroblasts with iron granules accumulating in a ring around the nucleus. - These iron deposits are visible with **Prussian blue staining**, confirming the diagnosis. *Severity of the disease is influenced by ALA synthase activity* - While defects in **heme synthesis** can cause sideroblastic anemia, the severity is not primarily or solely determined by **ALA synthase activity**. - Sideroblastic anemias involve diverse genetic and acquired causes, affecting various enzyme steps and pathways, not just specifically ALA synthase. *All of the options are false* - This statement is incorrect because the presence of **ringed sideroblasts** seen with Prussian blue staining is a hallmark diagnostic feature of sideroblastic anemia, making that option true. - This option would only be true if all other statements were false, which is not the case here. *Pyridoxine supplementation is the definitive treatment for all types of sideroblastic anemia* - **Pyridoxine (vitamin B6)** is a cofactor for some enzymes in the heme synthesis pathway, and about one-third of congenital sideroblastic anemias respond to it. - However, it is not a definitive treatment for **all types of sideroblastic anemia**, especially acquired forms or those with specific genetic mutations not responsive to pyridoxine.

Q: Which of the following genes is most commonly mutated in Juvenile myelomonocytic leukemia (JMML)?

PTPN11. ***PTPN11*** - **PTPN11** encodes the SHP2 protein, a non-receptor protein tyrosine phosphatase that plays a crucial role in the **RAS-MAPK signaling pathway**. - **Germline or somatic mutations** in PTPN11 are found in approximately **35% of JMML cases**, making it the **most commonly mutated gene** in this disorder. - These gain-of-function mutations lead to constitutive activation of RAS signaling, driving the myeloproliferative phenotype characteristic of JMML. - PTPN11 mutations are also associated with **Noonan syndrome**, and patients with Noonan syndrome have an increased risk of developing JMML. *KRAS* - **KRAS** is a proto-oncogene encoding a GTPase in the RAS-MAPK pathway. Mutations cause constitutive activation and uncontrolled cell proliferation. - KRAS mutations are found in approximately **15-20% of JMML cases**, making it the **second most common** genetic alteration in this disease. - While definitely associated with JMML, KRAS mutations are **less frequent than PTPN11 mutations**. *PTEN* - **PTEN** is a tumor suppressor gene regulating the PI3K-AKT pathway, involved in various cancers including Cowden syndrome and endometrial cancer. - PTEN mutations are **not associated with JMML** pathogenesis. *APC* - The **APC gene** is a tumor suppressor in the Wnt signaling pathway, critical for colon epithelial regulation. - APC mutations cause **familial adenomatous polyposis (FAP)** and colorectal cancer, but are **not implicated in JMML**.

Q: Which factor is primarily found in cryoprecipitate?

Factor VIII. ***Factor VIII*** - Cryoprecipitate is enriched with **Factor VIII**, essential for blood coagulation and hemophilia treatment [1]. - It also contains **fibrinogen**, **Factor XIII**, and von Willebrand factor, crucial for stable clot formation [1]. *Factor II* - Factor II, also known as **prothrombin**, is mainly found in **plasma**, not concentrated in cryoprecipitate. - It is not specifically extracted through cryoprecipitation, which focuses on fibrinogen and other factors. *Factor V* - Factor V is generally present in **plasma**, but not in significant amounts in cryoprecipitate. - It plays a role in the coagulation cascade but is not a primary component of cryoprecipitate. *Factor IX* - Factor IX is mainly associated with the **intrinsic pathway** of coagulation and is part of plasma, not concentrated in cryoprecipitate. - While it is vital for hemophilia B, it does not form part of the cryoprecipitate's key components. **References:** [1] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. Red Blood Cell and Bleeding Disorders, pp. 669-670.

Q: Richter's syndrome refers to which of the following malignant transformations?

CLL evolving into aggressive lymphoma. ***CLL evolving into aggressive lymphoma*** - **Richter's transformation** specifically describes the malignant transformation of Chronic Lymphocytic Leukemia (CLL) into a more aggressive form of B-cell non-Hodgkin lymphoma, most commonly **diffuse large B-cell lymphoma (DLBCL)**. - This transformation is characterized by a rapid clinical decline, palpable lymphadenopathy, and splenomegaly, with a distinct change in morphology and immunophenotype of the malignant cells. *Hairy cell leukemia evolving to AML* - Hairy cell leukemia (HCL) is a chronic lymphoproliferative disorder that rarely transforms into secondary malignancies; however, transformation into **acute myeloid leukemia (AML)** is not a hallmark of HCL and is not referred to as Richter's syndrome. - HCL is characterized by pancytopenia and distinctive hairy-looking lymphocytes, distinct from the progression pattern seen in Richter's. *Blast crisis in CML* - **Blast crisis** is the terminal phase of chronic myeloid leukemia (CML), where the number of myeloid blasts in the blood or bone marrow increases to >20%. - This is a progression of CML, a myeloproliferative neoplasm, and is distinct from the lymphoid transformation described by Richter's syndrome. *Splenic infiltration in NHL* - While non-Hodgkin lymphoma (NHL) can involve the spleen, **splenic infiltration** itself does not describe a malignant transformation syndrome like Richter's. - Richter's syndrome describes a transformation *from* CLL *to* a more aggressive lymphoma, not just a site of involvement for NHL.

Q: TEL-AML1 fusion is associated with?

ALL. ***ALL*** - The **TEL-AML1 fusion gene** (also known as ETV6-RUNX1) is a common chromosomal abnormality found in approximately 25% of cases of **B-cell precursor acute lymphoblastic leukemia (ALL)**, particularly in children. - This fusion creates an abnormal protein that interferes with normal blood cell development, leading to the uncontrolled proliferation of immature lymphocytes characteristic of ALL. *CLL* - **Chronic lymphocytic leukemia (CLL)** is a cancer of mature lymphocytes, specifically B cells, and is not associated with the TEL-AML1 fusion. - Typical genetic abnormalities in CLL include deletions or mutations in chromosomes 13q, 17p, 11q, and trisomy 12. *CML* - **Chronic myeloid leukemia (CML)** is characterized by the presence of the **Philadelphia chromosome (BCR-ABL1 fusion gene)**, which results from a translocation between chromosomes 9 and 22. - CML is a myeloproliferative neoplasm affecting myeloid stem cells, distinct from the lymphoid origin of ALL. *AML* - **Acute myeloid leukemia (AML)** involves the myeloid lineage and is associated with various chromosomal translocations and mutations, but **TEL-AML1 fusion is not characteristic of AML**. - Common genetic alterations in AML include t(8;21), inv(16), t(15;17) (PML-RARA), and mutations in FLT3, NPM1, or CEBPA.

Q: Flow cytometry is primarily used for analysis of which of the following cell types?

Lymphocytes. ***Lymphocytes*** - Flow cytometry is excellently suited for **lymphocyte analysis** due to their distinct surface markers (CD antigens) that can be labeled with fluorescent antibodies. - It allows for the **identification and quantification of various lymphocyte subsets** (e.g., T cells, B cells, NK cells), crucial in diagnosing immunodeficiencies, autoimmune diseases, and hematologic malignancies. *Erythrocytes* - While flow cytometry can detect erythrocytes, their primary role is oxygen transport, and they **lack cell surface markers** commonly analyzed by flow cytometry for classification. - **Complete blood count (CBC)** is the standard method for erythrocyte quantification and morphological analysis. *Platelets* - Flow cytometry can be used to study platelet activation and surface markers, but it's not their **primary or routine analytical tool** for mere count or general assessment. - **Automated hematology analyzers** are routinely used for platelet counts and basic morphology. *Basophil* - Basophils are a type of granulocyte and can be identified by flow cytometry, but they are a **very small percentage of circulating leukocytes**, making them less commonly the *primary* target of a typical flow cytometry panel focused on overall leukocyte populations. - While they can be analyzed, lymphocytes offer a much **broader range of clinical utility** due to their diverse subpopulations and roles in immunity and disease.

Q: Where are Dutcher bodies typically seen?

Bone marrow. ***Bone marrow*** - **Dutcher bodies** are **intranuclear inclusions** of immunoglobulin, characteristically seen in **plasma cells** within the bone marrow. - Their presence is a classic morphological feature of **Waldenström macroglobulinemia** and other lymphoproliferative disorders. *Brain* - The brain is not the typical site for finding Dutcher bodies; structures like **Lewy bodies** (Parkinson's disease) or **neurofibrillary tangles** (Alzheimer's disease) are seen here. - Dutcher bodies are specifically associated with plasma cell abnormalities and **B-cell lymphomas**. *Spleen* - While the spleen can be involved in various hematological malignancies, Dutcher bodies are not primarily identified within splenic tissue but rather in the **plasma cells** of the **bone marrow**. - Splenic pathology typically involves changes in spleen size and cellular architecture, not intranuclear inclusions like Dutcher bodies. *Liver* - The liver is not the primary site for the detection of Dutcher bodies. Liver pathology might show infiltration by malignant cells in some systemic diseases, but not these specific inclusions within hepatocytes or other liver cells. - **Councilman bodies** (apoptotic hepatocytes in viral hepatitis) are an example of liver-specific microscopic findings.

Q: Which condition is most commonly associated with basophilic leukocytosis?

Chronic Myeloid Leukemia (CML). ***Chronic Myeloid Leukemia (CML)*** - **Basophilic leukocytosis** is a characteristic feature of **CML**, resulting from the clonal expansion of myeloid stem cells. - The presence of **immature granulocytes**, including basophils, is key to diagnosing CML, particularly in the chronic phase. *Acute Myeloid Leukemia (AML)* - AML is characterized by an excessive proliferation of **myeloblasts** (immature myeloid cells) in the bone marrow and peripheral blood, not mature basophils. - While other myeloid lineages can be affected, basophilic leukocytosis is not a defining or common feature. *Acute Lymphoblastic Leukemia (ALL)* - ALL involves the uncontrolled proliferation of **lymphoblasts** (immature lymphoid cells). - This condition is specifically associated with the lymphoid lineage and does not typically cause an increase in myeloid cells like basophils. *Chronic Lymphocytic Leukemia (CLL)* - CLL is characterized by the accumulation of **mature, but dysfunctional, B lymphocytes**. - It involves the lymphoid lineage and does not lead to basophilic leukocytosis, which is a feature of myeloid disorders.

Question 1

A blood grouping test shows clumping with Anti-A serum, clumping with Anti-B serum, and no clumping in the control. What blood group does this indicate?

Accepted Answer

AB

Answer

A

Answer

B

Answer

O

Question 2

Which disease is characterized by the absence of the CD59 protein?

Accepted Answer

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Answer

Atypical Hemolytic Uremic Syndrome (aHUS)

Answer

Hereditary Spherocytosis

Answer

Autoimmune Hemolytic Anemia

Question 3

Which of the following statements about sideroblastic anemia is correct?

Accepted Answer

Prussian blue staining reveals ringed sideroblasts

Answer

All of the options are false

Answer

Severity of the disease is influenced by ALA synthase activity

Answer

Pyridoxine supplementation is the definitive treatment for all types of sideroblastic anemia

Question 4

Which of the following genes is most commonly mutated in Juvenile myelomonocytic leukemia (JMML)?

Accepted Answer

PTPN11

Answer

KRAS

Answer

PTEN

Answer

APC

Question 5

Which factor is primarily found in cryoprecipitate?

Accepted Answer

Factor VIII

Answer

Factor II

Answer

Factor V

Answer

Factor IX

Question 6

Richter's syndrome refers to which of the following malignant transformations?

Accepted Answer

CLL evolving into aggressive lymphoma

Answer

Hairy cell leukemia evolving to AML

Answer

Blast crisis in CML

Answer

Splenic infiltration in NHL

Question 7

TEL-AML1 fusion is associated with?

Accepted Answer

ALL

Answer

CLL

Answer

CML

Answer

AML

Question 8

Flow cytometry is primarily used for analysis of which of the following cell types?

Accepted Answer

Lymphocytes

Answer

Platelets

Answer

Erythrocytes

Answer

Basophils

Question 9

Where are Dutcher bodies typically seen?

Accepted Answer

Bone marrow

Answer

Brain

Answer

Spleen

Answer

Liver

Question 10

Which condition is most commonly associated with basophilic leukocytosis?

Accepted Answer

Chronic Myeloid Leukemia (CML)

Answer

Acute Myeloid Leukemia (AML)

Answer

Acute Lymphoblastic Leukemia (ALL)

Answer

Chronic Lymphocytic Leukemia (CLL)

Hematopathology — MCQs

Hematopathology — MCQs

On this page

Practice by Chapter

Want unlimited practice?